

ASX ANNOUNCEMENT

28 April 2021

Respiri Partnership with TerryWhite Chemmart Group

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is pleased to announce an agreement with TerryWhite Chemmart to sell and market wheezo™, commencing immediately.

As Australia’s largest pharmacy network with over 450 community pharmacies and with a commitment to providing expert health advice, TerryWhite Chemmart pharmacies are well placed to bring wheezo to asthma patients and assist with the overall improvement of asthma management. TerryWhite Chemmart provides high-quality, accessible and cost-effective community-based health care services and programs.

Respiri CEO and Managing Director, Mr Marjan Mikel was excited with the announcement: “Respiri continues to grow wheezo product availability in the pharmacy channel as we recognise the important role that pharmacies play with supporting asthma management and care. This agreement with Terry White Chemmart takes the number of pharmacies contracted to stock and sell wheezo to approximately 1,000 stores, representing an implied market footprint of 22% based on the total number of ex-hospital community pharmacies across the country.”

As previously announced to the market, the Company remains in active discussions with several other large pharmacy banner groups expects to make further ASX announcements once these discussions are finalised, and initial orders have commenced.

For further information about wheezo, follow the online link <https://wheezo.com>

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
 CEO & Managing Director
 Respiri Limited
 P: +61 408 462 873
 E: marjan@respiri.co

Mr Nicholas Smedley
 Executive Chairman
 Respiri Limited
 P: +61 447 074 160
 E: nicholas@respiri.co

™ wheezo is a trademark of Respiri Limited.

This ASX announcement dated 28 April 2021 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.